REGENXBIO Inc. (NASDAQ:RGNX) CEO Kenneth T. Mills Sells 15,000 Shares of Stock

REGENXBIO Inc. (NASDAQ:RGNX) CEO Kenneth T. Mills sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $18.19, for a total transaction of $272,850.00. Following the transaction, the chief executive officer now owns 408,035 shares in the company, valued at $7,422,156.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

REGENXBIO Price Performance

Shares of RGNX stock opened at $17.03 on Thursday. The firm has a fifty day moving average of $20.03 and a 200-day moving average of $17.85. REGENXBIO Inc. has a 12-month low of $11.83 and a 12-month high of $28.80.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.16). REGENXBIO had a negative return on equity of 68.18% and a negative net margin of 291.99%. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $34.01 million. During the same period in the prior year, the company earned ($1.38) EPS. The firm’s revenue was down 28.8% on a year-over-year basis. Research analysts anticipate that REGENXBIO Inc. will post -3.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Royal Bank of Canada upgraded shares of REGENXBIO from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $20.00 to $35.00 in a report on Friday, March 8th. Stifel Nicolaus restated a “buy” rating and issued a $40.00 price objective on shares of REGENXBIO in a report on Friday, April 12th. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Thursday, April 11th. Barclays increased their price objective on shares of REGENXBIO from $45.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, March 7th. Finally, SVB Leerink raised shares of REGENXBIO from a “market perform” rating to an “outperform” rating and set a $37.00 target price for the company in a research note on Wednesday, March 6th. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.45.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. grew its position in REGENXBIO by 2.8% in the second quarter. BlackRock Inc. now owns 8,268,972 shares of the biotechnology company’s stock valued at $165,297,000 after purchasing an additional 228,182 shares in the last quarter. Vanguard Group Inc. grew its position in REGENXBIO by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 4,440,838 shares of the biotechnology company’s stock valued at $79,713,000 after purchasing an additional 64,265 shares in the last quarter. JPMorgan Chase & Co. grew its position in REGENXBIO by 5.6% in the first quarter. JPMorgan Chase & Co. now owns 4,005,623 shares of the biotechnology company’s stock valued at $75,746,000 after purchasing an additional 211,146 shares in the last quarter. Finally, State Street Corp grew its position in REGENXBIO by 5.6% in the second quarter. State Street Corp now owns 2,801,494 shares of the biotechnology company’s stock valued at $69,197,000 after purchasing an additional 147,728 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.